Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report
暂无分享,去创建一个
Pierre-Stéphane Gsell | Ana Maria Henao-Restrepo | Ira M Longini | Adam J Kucharski | Anton Camacho | Ximena Riveros | Natalie E Dean | Marie Paule Kieny | N. Dean | W. Edmunds | A. Kucharski | I. Longini | M. Kieny | A. Diallo | A. Camacho | E. Higgs | M. Fallah | M. Doumbia | S. Kéïta | A. Henao-Restrepo | G. Enwere | X. Riveros | A. Vicari | C. Watson | Moussa Doumbia | Godwin Enwere | Andrea S Vicari | W J Edmunds | Mosoka Fallah | P. Gsell | Aminata Bagayoko | Sévérine Danmadji Nadlaou | A. Diallo | Djidonou A Honora | Thomas Mauget | D. Mory | Fofana Thierno Oumar | A. Toure | Conall H Watson | Elizabeth S Higgs | Sakoba Kéïta | Thomas Mauget | Alhassane Toure | Aminata Bagayoko | Séverine Danmadji Nadlaou | Abdourahamane Diallo | Abdourahmane Diallo | Diakite Mory | S. Keïta | Sakoba Keïta
[1] S. Yerly,et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. , 2015, The Lancet. Infectious diseases.
[2] T. Lancet. Ebola in west Africa: gaining community trust and confidence , 2014, The Lancet.
[3] John-Arne Røttingen,et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) , 2017, The Lancet.
[4] G. Rodier,et al. Social and cultural factors behind community resistance during an Ebola outbreak in a village of the Guinean Forest region, February 2015: a field experience. , 2016, International health.
[5] John-Arne Røttingen,et al. The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola , 2015, BMJ : British Medical Journal.
[6] John-Arne Røttingen,et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial , 2015, The Lancet.
[7] Ian Goodfellow,et al. Resurgence of Ebola Virus Disease in Guinea Linked to a Survivor With Virus Persistence in Seminal Fluid for More Than 500 Days , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.